PE20230090A1 - Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos - Google Patents

Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos

Info

Publication number
PE20230090A1
PE20230090A1 PE2022000419A PE2022000419A PE20230090A1 PE 20230090 A1 PE20230090 A1 PE 20230090A1 PE 2022000419 A PE2022000419 A PE 2022000419A PE 2022000419 A PE2022000419 A PE 2022000419A PE 20230090 A1 PE20230090 A1 PE 20230090A1
Authority
PE
Peru
Prior art keywords
antibody
stem cell
cell factor
fragment
methods
Prior art date
Application number
PE2022000419A
Other languages
English (en)
Inventor
Martin Phillips
Original Assignee
Opsidio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opsidio Llc filed Critical Opsidio Llc
Publication of PE20230090A1 publication Critical patent/PE20230090A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Referido a un anticuerpo o fragmento de este que se une especificamente al factor de las celulas madre (SCF) en donde el anticuerpo comprende una CDR1, CDR2 y CDR3 de cadena pesada que comprende las SEQ ID No. 1, 2 y 3, respectivamente; ademas CDR1, CDR2 y CDR3 de la cadena liviana que comprende las SEQ ID No. 4, 5 y 6, respectivamente. En donde dicho anticuerpo o fragmento de el bloquea la interaccion entre SCF y c-kit. Tambien se refiere a una molecula de acido nucleico que codifica el anticuerpo o fragmento de el, un vector de expresion, una celula huesped recombinante y un metodo para fabricar un anticuerpo que se une especificamente a la isoforma 248 del factor de la celula madre (SCF248); y su uso en el tratamiento para enfermedades y trastornos inflamatorios y/o fibroticos.
PE2022000419A 2019-09-16 2020-09-16 Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos PE20230090A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962900927P 2019-09-16 2019-09-16
PCT/US2020/050973 WO2021055408A1 (en) 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20230090A1 true PE20230090A1 (es) 2023-01-16

Family

ID=74868426

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000419A PE20230090A1 (es) 2019-09-16 2020-09-16 Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos

Country Status (20)

Country Link
US (5) US20220324957A1 (es)
EP (2) EP4031176A4 (es)
JP (2) JP2022548646A (es)
KR (1) KR20220079561A (es)
CN (1) CN114729036A (es)
AR (1) AR119979A1 (es)
AU (2) AU2020348295A1 (es)
BR (1) BR112022004776A2 (es)
CA (2) CA3154649A1 (es)
CL (1) CL2022000633A1 (es)
CO (1) CO2022003661A2 (es)
DO (1) DOP2022000058A (es)
EC (1) ECSP22022676A (es)
IL (1) IL291385A (es)
MX (1) MX2022003159A (es)
PE (1) PE20230090A1 (es)
TW (1) TW202124434A (es)
UY (1) UY38883A (es)
WO (2) WO2021055408A1 (es)
ZA (1) ZA202203272B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154649A1 (en) 2019-09-16 2021-03-25 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof in renal disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20002145B (en) * 1989-10-16 2000-06-25 Amgen Inc Us Stem Cell Factor
US5911988A (en) 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
ES2389047T3 (es) 2004-04-29 2012-10-22 Otsuka Pharmaceutical Co., Ltd. Anticuerpos específicos contra la glicoproteína VI y procedimientos de producción de estos anticuerpos
US20080248050A1 (en) 2006-06-30 2008-10-09 Uchicago Argonne, Llc Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine
US20110189093A1 (en) 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
CN103547288B (zh) 2011-01-10 2016-03-16 密执安大学评议会 干细胞因子抑制剂
KR101384360B1 (ko) 2012-05-04 2014-04-14 아주대학교산학협력단 Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
MY195443A (en) 2015-08-19 2023-01-21 Pfizer Tissue Factor Pathway Inhibitor Antibodies and uses Thereof
EP3393516A1 (en) 2015-12-22 2018-10-31 AbbVie Stemcentrx LLC Novel anti-upk1b antibodies and methods of use
CA3154649A1 (en) 2019-09-16 2021-03-25 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof in renal disease

Also Published As

Publication number Publication date
DOP2022000058A (es) 2022-08-31
AU2020348295A1 (en) 2022-04-07
EP4031176A1 (en) 2022-07-27
CA3154648A1 (en) 2021-03-25
JP2022547733A (ja) 2022-11-15
CL2022000633A1 (es) 2022-11-11
EP4031176A4 (en) 2023-11-29
KR20220079561A (ko) 2022-06-13
BR112022004776A2 (pt) 2022-06-21
AU2020351138A1 (en) 2022-03-31
ECSP22022676A (es) 2022-05-31
TW202124434A (zh) 2021-07-01
CO2022003661A2 (es) 2022-04-08
MX2022003159A (es) 2022-04-07
US11939373B2 (en) 2024-03-26
EP4031569A1 (en) 2022-07-27
JP2022548646A (ja) 2022-11-21
WO2021055408A1 (en) 2021-03-25
IL291385A (en) 2022-05-01
EP4031569A4 (en) 2023-10-18
UY38883A (es) 2021-04-30
ZA202203272B (en) 2022-12-21
US20210079084A1 (en) 2021-03-18
CA3154649A1 (en) 2021-03-25
US20220324957A1 (en) 2022-10-13
CN114729036A (zh) 2022-07-08
US20230019680A1 (en) 2023-01-19
US20240076367A1 (en) 2024-03-07
AR119979A1 (es) 2022-01-26
WO2021055409A1 (en) 2021-03-25
US20220340655A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
PE20190976A1 (es) Anticuerpos de union a cd3
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
CL2008002668A1 (es) Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp.
UY37758A (es) Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
EA202090275A2 (ru) Антитела против с5 с улучшенными фармакокинетическими характеристиками
CR20190009A (es) Anticuerpos anti-pd-1, un método de producción y un método para su uso.
CO6251322A2 (es) Polipeptidos dominios variables de anticuerpos y antagonistas
PE20121646A1 (es) Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica
CL2008003004A1 (es) Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos.
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
CL2009002004A1 (es) Anticuerpo o fragmento del mismo que se une al receptor de interleuquina 4 que comprende una region variable de cadena liviana y pesada; secuencias de acido nucleico que codifica dichas regiones; vector que comprende dicha secuencia; celula huesped; metodo para producir dicho anticuerpo; y uso de dicho anticuerpo para trastornos inmunologicos.
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
AR108779A1 (es) Anticuerpos
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
AR078796A1 (es) Composiciones y metodos para tratar trastornos inflamatorios
PE20161221A1 (es) Anticuerpos de il-21
PH12021550244A1 (en) Anti-btla antibody
CL2023001436A1 (es) Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso
PE20190415A1 (es) Anticuerpos anti-basigin humanizados y uso de los mismos
PE20210119A1 (es) Anticuerpos anti-apoc3 y metodos de uso de estos
NI201700022A (es) Anticuerpo anti-vasa y métodos de producción y uso de los mismos.
PE20191743A1 (es) Anticuerpos biespecificos anti-pd-l1-anti-tim3